Evidence map›Paper›PMID 37158488›Full record

ArticleEuropean journal of preventive cardiology2023

The underutilization of preventive cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance System, 2011-22.

Ahmed Sayed, Malak Munir, Daniel Addison, Abdelrahman I Abushouk, Susan F Dent, Tomas G Neilan, Anne Blaes, Michael G Fradley, Anju Nohria, Khaled Moustafa and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in European journal of preventive cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Cancer as a novel risk factor for major cardiovascular adverse events in secondary prevention.International journal of cardiology. Cardiovascular risk and prevention · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Cardio-oncology rehabilitation: are we ready?European heart journal supplements : journal of the European Society of Cardiology · 2024
    Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 3 countries.

Ahmed SayedFaculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID 0000-0003-0150-8917
Malak MunirFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Daniel AddisonCardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, OH, USA.
Abdelrahman I AbushoukDepartment of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
Susan F DentDuke Cancer Institute, Department of Medicine, Duke University, Durham, NC, USA.ORCID 0000-0002-9183-9340
Tomas G NeilanCardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Anne BlaesDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-5433-4810
Michael G FradleyCardio-Oncology Center of Excellence, Division of Cardiology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-8352-8975
Anju NohriaCardio-Oncology Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Khaled MoustafaFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Salim S ViraniDepartment of Medicine, Aga Khan University, Stadium Road, Karachi 74800, Pakistan.ORCID 0000-0001-9541-6954
Ain Shams University · EGAga Khan University · PKAlexandria University · EGBrigham and Women's Hospital · USCleveland Clinic · USDuke University · USHarvard University · USThe Ohio State University · USUniversity of Minnesota · USUniversity of Pennsylvania · US

Funding

Early Detection and Mechanisms of Cancer Immunotherapy Associated CardiotoxicityK23HL155890 · NHLBI · OHIO STATE UNIVERSITY · PI ADDISON, DANIEL · 2021 to 2024
$663k
NHLBI NIH HHS K23 HL155890NHLBI NIH HHS L30 HL149063
6 · The paper itself

Abstract

aimsThis study aimed to characterize the influence of a cancer diagnosis on the use of preventive cardiovascular measures in patients with and without cardiovascular disease (CVD). METHODS AND

resultsData from the Behavioural Risk Factor Surveillance System Survey (spanning 2011-22) were used. Multivariable logistic regression models adjusted for potential confounders were applied to calculate average marginal effects (AME), the average difference in the probability of using a given therapy between patients with and without cancer. Outcomes of interest included the use of pharmacological therapies, physical activity, smoking cessation, and post-CVD rehabilitation. Among 5 012 721 respondents, 579 114 reported a history of CVD (coronary disease or stroke), and 842 221 reported a diagnosis of cancer. The association between cancer and the use of pharmacological therapies varied between those with vs. without CVD (P-value for interaction: <0.001). Among patients with CVD, a cancer diagnosis was associated with a lower use of blood pressure-lowering medications {AME: -1.46% [95% confidence interval (CI): -2.19% to -0.73%]}, lipid-lowering medications [AME: -2.34% (95% CI: -4.03% to -0.66%)], and aspirin [AME: -6.05% (95% CI: -8.88% to -3.23%)]. Among patients without CVD, there were no statistically significant differences between patients with and without cancer regarding pharmacological therapies. Additionally, cancer was associated with a significantly lower likelihood of engaging in physical activity in the overall cohort and in using post-CVD rehabilitation regimens, particularly post-stroke rehabilitation.

conclusionPreventive pharmacological agents are underutilized in those with cancer and concomitant CVD, and physical activity is underutilized in patients with cancer in those with or without CVD. LAY SUMMARY: •This paper compared the use of preventive cardiovascular measures, both pharmaceutical and non-pharmaceutical, in patients with and without cancer.•In patients with cardiovascular disease and cancer, there is a lower use of preventive cardiovascular medications compared with those with cardiovascular disease but without cancer. This includes a lower utilization of blood pressure-lowering medications, cholesterol-lowering medications, and aspirin.•Patients with cancer reported lower levels of exercise but higher levels of smoking cessation compared with those without cancer.

Indexed as

Anticholesteremic AgentsCardiovascular DiseasesNeoplasmsAspirinBehavioral Risk Factor Surveillance SystemHumansRisk FactorsAnticholesteremic AgentsAspirinBlood pressureCancerCardio-oncologyCardiovascular preventionExerciseLipids

Identifiers

PMID37158488
PMCPMC10516320
OpenAlexW4375955105

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.